What is the YMRS score?

The Young Mania Rating Scale (YMRS) is an 11-item clinician-administered scale that measures manic symptom severity in bipolar disorder. It was published by Young et al. in the British Journal of Psychiatry (1978) and has become the gold standard mania severity measure. YMRS scores range 0-60, with higher scores indicating more severe mania.

How do you administer the YMRS?

YMRS is administered by a trained clinician through a structured clinical interview. The clinician rates 11 items based on patient interview and direct behavioral observation over the past 48 hours. Items are rated on scales of 0-4 (7 items) or 0-8 (4 weighted items: irritability, speech, thought content, disruptive behavior). Total administration time is approximately 15-30 minutes.

What is the YMRS score interpretation?

YMRS interpretation: 0-12 = absent/remission (euthymia); 13-20 = mild mania; 21-35 = moderate mania; above 35 = severe mania. YMRS 12 or below is the standard clinical remission threshold used in bipolar trials and treatment guidelines. YMRS above 35 indicates severe mania typically requiring intensive inpatient psychiatric treatment.

What is the YMRS remission criteria?

The standard YMRS remission criterion in clinical trials and practice guidelines (including CANMAT 2018) is a score of 12 or below. Response (50% reduction from baseline) is a secondary criterion. Clinical treatment goal during acute mania should be achieving YMRS remission, not just response, as scores above 12 still indicate clinically meaningful manic symptoms.

What treatments reduce YMRS scores?

FDA-approved first-line antimanic agents with YMRS reduction evidence: lithium, valproate/divalproex, aripiprazole, asenapine, cariprazine, olanzapine, quetiapine, risperidone, and ziprasidone. Combination therapy (mood stabilizer + atypical antipsychotic) produces greater YMRS reduction than monotherapy in randomized trials. ECT is effective for severe or treatment-resistant mania.

What is the difference between bipolar I and bipolar II mania?

Bipolar I requires at least one full manic episode (YMRS typically 20+, lasting 7+ days, causing functional impairment or requiring hospitalization). Bipolar II requires hypomanic episodes (milder severity, usually 3-7 days, no psychosis or hospitalization required) plus at least one major depressive episode. YMRS was developed and validated for bipolar I mania; hypomania typically scores 10-18.

What does a YMRS score above 20 mean?

A YMRS score of 21-35 indicates moderate mania with clinically significant impairment. Patients require immediate psychiatric evaluation and usually initiation or adjustment of antimanic medications. YMRS above 35 represents severe mania, often with psychotic features, requiring urgent psychiatric hospitalization, high-dose antimanic treatment, and intensive monitoring.

Can YMRS be used for mixed features bipolar disorder?

YMRS captures the manic pole of mixed features but does not assess the depressive pole. For bipolar episodes with mixed features (DSM-5 specifier requiring 3+ depressive symptoms during mania), YMRS should be combined with a depression measure (MADRS or HDRS) to quantify both poles simultaneously. Mixed states have higher suicide risk than pure mania and require different treatment (antipsychotics preferred; antidepressants contraindicated).

What is the inter-rater reliability of YMRS?

YMRS has excellent inter-rater reliability: ICC 0.93 in the original validation study (Young et al. 1978, N=70 manic inpatients). Internal consistency alpha 0.80. Adequate inter-rater reliability requires that clinicians use the same time frame (past 48 hours) and conduct a structured interview rather than relying solely on self-report from the patient.

What antimanic medication should be used for severe mania (YMRS > 35)?

Severe mania (YMRS above 35) typically requires combination therapy for rapid symptom control: an atypical antipsychotic (olanzapine, risperidone, or quetiapine provide fastest onset) plus a mood stabilizer (lithium or valproate). Benzodiazepines (lorazepam, clonazepam) are useful for acute agitation. Oral or IM antipsychotics may be required for patients refusing medication. ECT is an option for refractory severe mania.

Does YMRS assess suicidal ideation in mania?

YMRS does not include a suicidal ideation item. However, manic patients — particularly those with mixed features or dysphoric mania — have elevated suicide risk. Always conduct a separate suicidal ideation and safety assessment in addition to YMRS. Bipolar disorder carries the highest suicide rate of all psychiatric diagnoses (15-20% lifetime risk of suicide completion).

Online Medical Tools — YMRS

Printed on 9/3/2026

For informational purposes only. This is not medical advice.

Mental Health

YMRS

YMRS is a structured clinician rating scale for mania severity in bipolar-spectrum and related presentations. It is frequently used for baseline severity and longitudinal treatment-response tracking.

Formula: YMRS total = sum of 11 items with weighted items (max score 60).

Elevated mood

Increased motor activity/energy

Sexual interest

Sleep (reduced need)

Irritability

Speech (rate and amount)

Language/thought disorder

Content (grandiosity/psychotic features)

Disruptive/aggressive behavior

Appearance

Insight

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Clinician Rates 11 Items Based on Interview and Observation

A trained clinician rates 11 items based on patient interview and direct behavioral observation covering the past 48 hours. Items assess elevated mood, increased motor activity, sexual interest, reduced sleep need, irritability, pressured speech, language and thought disorder, thought content (grandiosity/psychosis), disruptive behavior, appearance, and insight.

Score Each Item on 0-4 or 0-8 Scale and Sum

Seven items are scored 0-4 (elevated mood, motor activity, sexual interest, sleep, language/thought disorder, appearance, insight). Four items are weighted and scored 0-8 (irritability, speech rate/amount, thought content, disruptive/aggressive behavior). Sum all 11 items for a total of 0-60.

Interpret Mania Severity and Guide Treatment

YMRS interpretation: 0-12 = absent/remission (euthymia); 13-20 = mild mania; 21-35 = moderate mania; above 35 = severe mania. YMRS 12 or below is the standard remission threshold in most bipolar clinical trials and treatment guidelines (CANMAT 2018).

Who Uses the YMRS

Bipolar Disorder Mania Severity Monitoring

Psychiatrists

YMRS is the standard clinician-administered mania severity scale for bipolar I disorder. It provides a reproducible, quantified measure of manic symptom burden across the 11 core mania domains, enabling objective comparison across visits and communication of severity between treatment providers.

Treatment Response Assessment for Antimanic Agents

Psychopharmacologists

All major FDA-approved antimanic medications (lithium, valproate, atypical antipsychotics) demonstrated efficacy via YMRS reduction in pivotal clinical trials. Serial YMRS monitoring every 1-2 weeks during acute mania treatment provides objective evidence of medication response or inadequate response requiring treatment escalation.

Clinical Trial Primary Endpoint for Mania

Clinical Researchers

YMRS is the FDA-required primary efficacy endpoint for all drug development in bipolar I mania. The 50% reduction in YMRS from baseline is the standard response criterion, while YMRS 12 or below is the remission criterion used universally in bipolar mania trials.

Psychiatric Hospitalization Admission Criteria

Inpatient Psychiatric Teams

YMRS is used to document objective mania severity for hospitalization decision-making, treatment intensity planning, and monitoring progress toward discharge readiness. YMRS above 35 (severe) typically indicates requirement for intensive inpatient treatment with rapid dose escalation.

Outpatient Mood Stability Tracking

Bipolar Care Teams

For bipolar patients in maintenance treatment, quarterly YMRS monitoring provides early detection of subclinical manic shifts (prodromal mania) before full episodes develop. Scores trending upward from baseline euthymia (0-12) can trigger early intervention including medication adjustment and behavioral strategies.

Pro Tips

YMRS Is Clinician-Rated — Not a Self-Report Scale

YMRS requires trained clinician administration based on structured interview and behavioral observation. It is not validated for self-report and must not be administered as a questionnaire. Clinician observation of motor behavior, speech, and appearance during the interview is integral to accurate scoring.

Rate the Past 48 Hours — Not Longer Time Periods

YMRS is specifically designed to assess symptom severity in the past 48 hours. Using a longer time frame (past week, past month) will produce unreliable scores. For longer-term mood tracking, use Clinical Global Impressions-Bipolar (CGI-BP) or the Life Chart Methodology.

Elevated Mood Is Not Always Present in Mania — Look for Irritable Mania

Classic euphoric mania is not the only presentation. Dysphoric or irritable mania presents with elevated irritability (item 5) without euphoria (item 1 may score 0-1). Irritable mania is more common in women, in adolescents, and in bipolar II. Missing irritable mania is the most common clinical error in bipolar diagnosis.

Thought Content Item Covers Multiple Psychotic Features

YMRS item 8 (thought content) includes grandiosity, paranoia, religiosity, and frank psychotic delusions — not just delusions. Grandiose ideas short of full delusions score 2, paranoid ideas score 4, clear delusions score 6-8. Always probe all thought content domains during interview.

Language and Thought Disorder Correlates With Psychotic Severity

Item 7 (language/thought disorder) captures flight of ideas, tangentiality, and loose associations. High scores on both item 7 and item 8 (thought content) indicate manic psychosis and warrant antipsychotic treatment alongside mood stabilizers.

Insight Is Heavily Weighted in Severe Mania

Insight (item 11) is one of the most clinically important items. Patients with mania typically have poor insight, denying illness and refusing medication. Poor insight (score 4) indicates high risk for medication non-adherence and need for involuntary treatment consideration.

YMRS 12 or Below Is the Universal Remission Threshold

YMRS 12 or below is the standard remission criterion in most bipolar clinical trials and is referenced in CANMAT 2018 bipolar I guidelines. Clinical treatment goal during acute mania management is achieving YMRS remission, not just response (50% reduction).

First-Line Antimanic Treatments All Reduce YMRS

FDA-approved first-line options for bipolar I mania with YMRS-reduction evidence: lithium, valproate, aripiprazole, asenapine, cariprazine, olanzapine, quetiapine, risperidone, ziprasidone. The choice among these depends on side effect profile, polarity history, and individual patient factors.

Combine YMRS With MADRS When Mixed Features Are Suspected

DSM-5 allows a 'with mixed features' specifier when manic episodes include depressive symptoms. Combining YMRS with MADRS or Hamilton Depression Rating Scale (HDRS) enables quantification of both pole severity simultaneously, crucial for treatment planning (antipsychotics preferred over antidepressants in mixed states).

ECT Is Effective for Severe or Treatment-Resistant Mania

Electroconvulsive therapy (ECT) has strong evidence for severe mania with YMRS above 35 or treatment-resistant cases. ECT produces rapid YMRS reduction, often within 3-5 treatments, and is particularly valuable when pharmacotherapy is contraindicated or when rapid response is required.

Common Questions About Your Results

Dysphoric mania presents with prominent irritability (YMRS item 5 scoring high) rather than euphoric elevated mood (item 1 may score 0-1). Patients may deny feeling 'high' or euphoric but demonstrate pressured speech, decreased sleep, grandiosity, and poor insight. Always score all 11 YMRS items regardless of mood valence, and supplement with PHQ-9 or MADRS to capture depressive symptom co-occurrence (mixed features).

YMRS was validated in bipolar I manic inpatients. Its validity and normative data for bipolar II hypomanic episodes is less established. Hypomania is by definition less severe than mania, typically resulting in lower YMRS scores (often 10-18). For bipolar II monitoring, YMRS can be used but some clinicians prefer the Hypomania Checklist (HCL-32) or Young Mania Rating Scale with modified thresholds.

Evidence-Based Methodology

YMRS published by Young et al. (Br J Psychiatry 1978) from 70 manic inpatients. Inter-rater reliability ICC 0.93. Internal consistency alpha 0.80. Widely used as the primary efficacy endpoint in bipolar mania clinical trials (FDA-required for drug approval). YMRS 12 or lower as remission threshold used in CANMAT 2018 bipolar guidelines. All major antimanic agents (lithium, valproate, atypical antipsychotics) demonstrated YMRS reduction in pivotal trials. CANMAT 2018 and BAP 2016 guidelines reference YMRS for mania severity staging.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Higher YMRS totals reflect greater manic symptom burden and can guide urgency and intensity of mood-stabilization planning.

When to Use This Tool

Use in clinician-led bipolar/mania evaluation and serial monitoring contexts.

Limitations

YMRS requires clinician training and consistent interviewing. It is severity-focused and does not independently establish full DSM diagnostic criteria.

For related assessments, see MDQ Screener, PHQ-9 and HAM-A.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools

Mental Health

MDQ Screener

Screen for bipolar-spectrum symptom patterns using the Mood Disorder Questionnaire (MDQ) criteria framework.

Open Mental Health

PHQ-9

Free PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).

Open Mental Health

HAM-A

Rate clinician-observed anxiety severity using the 14-item Hamilton Anxiety Rating Scale.

Open

Frequently Asked Questions

YMRS is the FDA-required primary efficacy endpoint for regulatory approval of all antimanic medications. All first-line approved treatments (lithium, valproate, aripiprazole, olanzapine, quetiapine, risperidone, cariprazine) demonstrated significant YMRS reduction vs placebo in pivotal trials. A statistically significant YMRS reduction (typically 4-8 points advantage over placebo at 3 weeks) is required for drug approval.

Online Medical Tools — YMRS

YMRS

How It Works

Clinician Rates 11 Items Based on Interview and Observation

Score Each Item on 0-4 or 0-8 Scale and Sum

Interpret Mania Severity and Guide Treatment

Who Uses the YMRS

Bipolar Disorder Mania Severity Monitoring

Treatment Response Assessment for Antimanic Agents

Clinical Trial Primary Endpoint for Mania

Psychiatric Hospitalization Admission Criteria

Outpatient Mood Stability Tracking

Pro Tips

YMRS Is Clinician-Rated — Not a Self-Report Scale

Rate the Past 48 Hours — Not Longer Time Periods

Elevated Mood Is Not Always Present in Mania — Look for Irritable Mania

Thought Content Item Covers Multiple Psychotic Features

Language and Thought Disorder Correlates With Psychotic Severity

Insight Is Heavily Weighted in Severe Mania

YMRS 12 or Below Is the Universal Remission Threshold

First-Line Antimanic Treatments All Reduce YMRS

Combine YMRS With MADRS When Mixed Features Are Suspected

ECT Is Effective for Severe or Treatment-Resistant Mania

Common Questions About Your Results

Evidence-Based Methodology

Clinical Content Trust

How to Interpret Your Result

When to Use This Tool

Limitations

Changelog

Related Tools

MDQ Screener

PHQ-9

HAM-A

Further Reading

Mental Health Screening Guide: Depression, Anxiety, Substance Use, and Cognitive Assessment

Frequently Asked Questions